China SXT Prices $9M Registered Direct Offering with Highly Dilutive Zero-Price Warrants
SXTC is trading near its 52-week low of $0.307 (19% below the low) on elevated volume (43× avg).
Summary
China SXT Pharmaceuticals is raising $9 million in a registered direct offering with warrants that could more than double shares outstanding through a zero-cash exercise feature, adding to a string of highly dilutive financings.
Key Events · Financing and Capital Events · SXTC
-
$9M Registered Direct Offering Priced
The company is selling 4.5 million units at $2.00 each, consisting of one Class A ordinary share and one warrant, for gross proceeds of $9 million before fees.
-
Zero-Price Warrants Could Add 63M Shares
Each warrant has a $3.20 exercise price but includes a zero-price exercise option when the stock's 10-day VWAP is below $3.20, with a floor price of $0.40. If all warrants are exercised at the floor, up to 63 million additional shares would be issued with no cash proceeds to the company.
-
Immediate Dilution of $1.60 Per Share
Pro forma as-adjusted net tangible book value after the offering drops to $0.40 per share, meaning new investors pay $2.00 for shares with a book value of $0.40, while existing shareholders see their book value cut by $0.49 per share.
-
Net Proceeds of ~$8.28M After Fees
After a 7.0% placement agent fee ($630,000) and estimated expenses, the company expects to receive approximately $8.28 million, to be used for working capital and general corporate purposes.
Analysis · SXTC · Life Sciences
China SXT is raising $9 million through a registered direct offering of 4.5 million units at $2.00 each, with warrants that can be exercised for zero cash, potentially adding up to 63 million shares — more than doubling the current outstanding count. The warrants' zero-price exercise feature kicks in when the stock trades below $3.20, and with the floor price set at $0.40, the company could issue a massive number of shares without receiving any additional cash. This comes on the heels of a $30 million toxic financing announced just weeks ago and an existing $100 million ATM program, painting a picture of a company burning through cash and resorting to deeply dilutive structures. The stock is trading near its 52-week low, and this offering, priced at a premium to the current market, may provide short-term relief but sets up significant overhang and potential dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTC was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.31 to $1,046.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.